Added to YB: 2025-09-22
Pitch date: 2025-09-18
NANO.PA [neutral]
Nanobiotix S.A.
+84.98%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.
Market Cap
EUR 892.9M
Pitch Price
EUR 10.52
Price Target
N/A
Dividend
N/A
EV/EBITDA
-21.38
P/E
-17.00
EV/Sales
90.10
Sector
Biotechnology
Category
growth
Nanobiotix (NANO France): melanoma results reinforce confidence in NBTXR3
NANO.PA (quick overview): Phase I melanoma results show 50% objective response in anti-PD1 resistant patients, strong safety vs competitors like Iovance's Amtagvi. Disease control rate high, overall survival beats benchmarks. Local/systemic correlation validates platform. Phase III NANORAY-312 interim mid-2026.
Read full article (1 min)